Wedbush Expects Increased Earnings for Mersana Therapeutics

Mersana Therapeutics, Inc. (NASDAQ:MRSN) – Equities research analysts at Wedbush boosted their Q2 2025 EPS estimates for Mersana Therapeutics in a note issued to investors on Thursday, May 15th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($0.20) per share for the quarter, up from their prior estimate of ($0.23). Wedbush has a “Outperform” rating and a $3.00 price target on the stock. The consensus estimate for Mersana Therapeutics’ current full-year earnings is ($0.62) per share. Wedbush also issued estimates for Mersana Therapeutics’ Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.68) EPS, Q1 2026 earnings at ($0.12) EPS, Q2 2026 earnings at ($0.13) EPS, Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.11) EPS, FY2026 earnings at ($0.49) EPS and FY2027 earnings at ($0.46) EPS.

Other equities analysts have also recently issued research reports about the company. William Blair assumed coverage on Mersana Therapeutics in a report on Thursday, February 6th. They issued an “outperform” rating for the company. Truist Financial boosted their target price on shares of Mersana Therapeutics from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, May 16th. Finally, Guggenheim reaffirmed a “buy” rating and set a $5.00 price target on shares of Mersana Therapeutics in a research note on Friday, May 16th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $5.20.

Mersana Therapeutics Price Performance

Shares of NASDAQ MRSN opened at $0.39 on Monday. The company has a debt-to-equity ratio of 13.35, a current ratio of 2.35 and a quick ratio of 2.35. Mersana Therapeutics has a 1-year low of $0.26 and a 1-year high of $2.83. The company has a market capitalization of $48.61 million, a price-to-earnings ratio of -0.64 and a beta of 1.32. The business has a 50-day moving average of $0.36 and a 200-day moving average of $0.99.

Mersana Therapeutics (NASDAQ:MRSN) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.02. Mersana Therapeutics had a negative net margin of 214.20% and a negative return on equity of 401.37%. The company had revenue of $2.75 million during the quarter, compared to the consensus estimate of $6.05 million.

Institutional Trading of Mersana Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Novo Holdings A S bought a new position in Mersana Therapeutics during the 4th quarter valued at $6,078,000. SG Americas Securities LLC lifted its position in shares of Mersana Therapeutics by 28.7% during the fourth quarter. SG Americas Securities LLC now owns 112,291 shares of the company’s stock worth $161,000 after purchasing an additional 25,058 shares during the last quarter. Renaissance Technologies LLC raised its stake in Mersana Therapeutics by 23.0% during the fourth quarter. Renaissance Technologies LLC now owns 606,285 shares of the company’s stock valued at $867,000 after buying an additional 113,566 shares in the last quarter. Sei Investments Co. bought a new position in Mersana Therapeutics during the 4th quarter worth approximately $99,000. Finally, Cubist Systematic Strategies LLC acquired a new position in shares of Mersana Therapeutics in the 4th quarter worth approximately $65,000. Institutional investors own 93.92% of the company’s stock.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.